Research questions to explore with AI

Answer all questions below about the company in ENGLISH using the most up-to-date information available TODAY. GENERAL RULES - Before each answer, repeat the question exactly. - Each answer must be concise (maximum 100 words). - Write from the perspective of a VALUE INVESTOR. - Include concrete numbers whenever relevant (growth rates, margins, valuation multiples, debt ratios, market share, dividend yield, etc.). - If exact data is unavailable, explicitly say so instead of guessing. - Clearly distinguish facts from opinions or assumptions. - When comparing with competitors or the industry, provide numbers whenever possible. - Focus on information that helps determine whether the company is a high-quality long-term investment rather than short-term speculation. - Mention both positive and negative aspects whenever applicable. - Use recent financial reports, earnings releases and reliable market data where relevant. - If a question cannot be answered because data is unavailable or not applicable, explicitly state that. - Do not provide generic textbook explanations unless necessary to answer the question. - Keep every answer practical and investment-oriented. At the end, write a concise summary (maximum 200 words) that answers: - Is the company fundamentally attractive? - What are its biggest strengths? - What are its biggest risks? - Is the recent stock decline mainly due to temporary market sentiment or deterioration of the underlying business? - Does the company deserve a place on a value investor's watchlist?

• BUSINESS
• What does the Amgen do?
• How does the Amgen make money?
• What are the main products and services of the Amgen?
• How long has the Amgen existed?
• Is the business model of the Amgen simple and easy to understand?
• Does the Amgen operate in a stable industry?
• Is the industry in which the Amgen operates attractive and profitable?
• How concentrated is the industry of the Amgen? What market share do the five largest competitors control?
• Who are the biggest competitors of the Amgen?
• Is the Amgen outperforming its competitors?
• WHY IS THE STOCK DOWN?
• Why is the Amgen stock down recently?
• Did anything fundamentally change in the Amgen's business?
• Are the problems of the Amgen company-specific or industry-wide?
• Is the recent share price decline of the Amgen mainly a market overreaction rather than a deterioration in fundamentals?
• What are the latest important news about the Amgen?
• Has the Amgen stock been in a long-term decline?
• EARNINGS & CASH FLOW
• Did the recent earnings of the Amgen miss analysts' expectations while revenue, earnings per share and operating cash flow still improved?
• Is operating cash flow of the Amgen positive and growing?
• How has the free cash flow of the Amgen developed during the last five years?
• Has the Amgen consistently generated free cash flow?
• Is the Cash Flow-to-Sales ratio of the Amgen consistently above 5%?
• Did revenue decline while net income increased at the Amgen?
• Has the Amgen ever generated an operating profit?
• What mainly drove the profitability of the Amgen during the last five years?
• BALANCE SHEET
• How clean is the balance sheet of the Amgen?
• Is the leverage of the Amgen reasonable?
• Has debt as a percentage of total assets declined at the Amgen?
• Describe the debt structure of the Amgen.
• How have inventories developed at the Amgen?
• How have accounts receivable developed compared to revenue at the Amgen?
• Has inventory turnover improved or deteriorated at the Amgen?
• How significant were one-time charges at the Amgen in recent years?
• RETURNS
• Is the return on equity of the Amgen consistently above 10% (or 12% for financial companies)?
• Is the return on invested capital of the Amgen consistently above its weighted average cost of capital?
• How have return on equity, return on assets and return on invested capital developed over the last five years?
• MOAT
• Does the Amgen have durable competitive advantages?
• Does the Amgen have strong pricing power?
• How does the Amgen protect itself from competitors?
• Does the Amgen benefit from network effects?
• Does the Amgen have cost advantages?
• Does the Amgen own valuable intangible assets?
• Are switching costs high for customers of the Amgen?
• How loyal are customers of the Amgen?
• Describe the customer experience of the Amgen.
• Is customer engagement recurring?
• Is there customer concentration risk?
• GROWTH
• Where does the future growth of the Amgen come from?
• Is the future growth of the Amgen sustainable?
• Does the Amgen rely on acquisitions to grow?
• Has the Amgen been expanding aggressively?
• Is the order intake of the Amgen growing or stable?
• Is the business of the Amgen scalable?
• Can the Amgen keep pace with inflation?
• Is the Amgen highly cyclical?
• MANAGEMENT
• Are management incentives aligned with long-term shareholders of the Amgen?
• Has management of the Amgen allocated capital intelligently?
• Does the Amgen have an active share buyback program?
• Has the number of outstanding shares of the Amgen increased significantly? Why?
• Were there any significant insider purchases or sales at the Amgen recently?
• VALUATION
• Is the Amgen significantly undervalued?
• Is the Price-to-Earnings ratio of the Amgen attractive compared to peers?
• Does the current valuation of the Amgen provide a sufficient margin of safety?
• What level of future growth is already implied by the current valuation of the Amgen?
• How does the share price of the Amgen compare to its Net Asset Value?
• DIVIDENDS
• Are the dividends of the Amgen sustainable?
• How has the dividend of the Amgen developed during the last ten years?
• RISKS
• What are the biggest risks in investing in the Amgen?
• What is currently the biggest problem of the Amgen?
• Are there potential future disruptors of the Amgen, including Artificial Intelligence?
• Is Artificial Intelligence an existential threat to the Amgen?
• What would most likely cause a permanent loss of capital for investors in the Amgen?
• List the five biggest red flags that would stop a conservative value investor from investing in the Amgen today.
• MARKET
• How high are the trading volumes of the Amgen stock in Germany?
• Is the bid-ask spread of the Amgen during German trading hours reasonably small?
• Who typically owns the Amgen? Are institutional investors dominant?
• Describe the typical psychology of investors in the Amgen.
• PIOTROSKI
• Piotroski F-Score 1: Is the Amgen's net income positive?
• Piotroski F-Score 2: Is the Amgen's operating cash flow positive?
• Piotroski F-Score 3: Has the Amgen's return on assets improved?
• Piotroski F-Score 4: Is the Amgen's operating cash flow greater than net income?
• Piotroski F-Score 5: Has long-term debt relative to total assets decreased?
• Piotroski F-Score 6: Has the current ratio improved?
• Piotroski F-Score 7: Has the Amgen avoided meaningful share dilution?
• Piotroski F-Score 8: Has the gross margin improved?
• Piotroski F-Score 9: Has the asset turnover improved?
• What is the overall Piotroski F-Score of the Amgen?
• JIM COLLINS
• Jim Collins - Company Decline - Stage 1: Is the Amgen showing signs of arrogance or complacency after past success?
• Jim Collins - Company Decline - Stage 2: Has the Amgen expanded beyond its core business in pursuit of growth instead of profitability?
• Jim Collins - Company Decline - Stage 3: Is management of the Amgen ignoring or downplaying warning signs?
• Jim Collins - Company Decline - Stage 4: Is the Amgen relying on acquisitions, restructuring or other 'miracle' solutions instead of fixing core problems?
• Jim Collins - Company Decline - Stage 5: Is the Amgen at risk of becoming irrelevant or entering a long-term decline?
• FINAL DECISION
• Does the Amgen pass the minimum quality hurdle for a value investor?
• Should the Amgen remain on a value investor's watchlist?
• Would you invest €600 in the Amgen today? Why or why not?
• Give the Amgen a score from 1 to 10 for Business Quality, Competitive Advantage, Management, Financial Strength, Cash Flow Quality, Growth Potential, Valuation, Risk and Margin of Safety. Also calculate the overall score out of 100.
• Based on everything above, classify the Amgen as one of: Strong Buy, Buy, Watchlist, Wait or Avoid.
• What is today's date?